BRCA2 and ovarian serous adenocarcinoma: Data from TCGA reported that approximately 8% of ovarian carcinomas harbor defective mutations in NER genes,99 and Ceccaldi and coworkers identified a subgroup of high‐grade serous ovarian cancers characterized by NER alterations and a longer survival (similar to those harboring BRCA1/BRCA2 mutations) compared to those with wild‐type (WT) NER.100